Avalo Therapeutics (AVTX) Other financing activities (2017 - 2026)

Avalo Therapeutics' Other financing activities history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 98.55% YoY) and the FY2022 annual result came in at $73000.0, down 80.05% from the prior year.
• Other financing activities was $2.2 million for Q1 2026 at Avalo Therapeutics, up from -$40000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $142.7 million in Q4 2024 and bottomed at -$67000.0 in Q3 2023.
• A 5-year average of $29.0 million and a median of $67000.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities jumped 11131.34% — and 2025, when it plunged 100.03%.
• Avalo Therapeutics' Other financing activities stood at $48000.0 in 2022, then slumped by 239.58% to -$67000.0 in 2023, then jumped by 213085.07% to $142.7 million in 2024, then sank by 100.03% to -$40000.0 in 2025, then surged by 5545.0% to $2.2 million in 2026.
• Business Quant data shows AVTX's Other financing activities at $2.2 million in Q1 2026, -$40000.0 in Q4 2025, and $40000.0 in Q3 2025.